navicixizumab

·Code: OMP-305B83

navicixizumab: developed by 2 companies.

What we can confirm

No verified FDA or trial count is available.

Choose the developer to investigate (optional)BioSniper will not guess the developer.

What it means

More than one developer is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.

What to watch

Evidence is limited; missing information remains unknown.

BioSniper AIPage evidence connected

Prepared research question

What is verified about navicixizumab, and what remains unknown?

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Late line ovarian cancerAdvanced solid tumors, second-line metastatic colorectal cancer, platinum-resistant ovarian cancer

No additional listed-company sponsor is linked.

Development Pipeline (2)

Company	Phase	Indication
Mereo BioPharma Group plc (MREO) Late line ovarian cancer	Phase 1	Late line ovarian cancer
OncoMed Pharmaceuticals Inc (OMED) Advanced solid tumors, second-line metastatic colorectal can…	Phase 2	Advanced solid tumors, second-line metastatic colorectal can...

navicixizumab evidence translation